EUVIMEDEUVIMED entdecken
Open Access

Leveraging Model Integrated Bioequivalence (MIBE) to Address Regulatory Concerns and Waive Repeat Bioequivalence Studies—A Case Study with Clopidogrel

Mathangi Gopalakrishnan iD, Adithya Karthik Bhattiprolu, Joga Gobburu, Rajkumar Boddu, Veena Kambam, Sohel Mohammed Khan, Anuj Kumar Saini, Sivacharan Kollipara

The Journal of Clinical Pharmacology · 2026

DOI: 10.1002/jcph.70142 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Pharmacology, 2026. Verfasst von Mathangi Gopalakrishnan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Center for Translational Medicine, University of Maryland Baltimore, Baltimore, MD, USA. Hauptthemen laut MEDLINE: Clopidogrel, Platelet Aggregation Inhibitors, Models, Biological. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Dr. Reddy's Laboratories Ltd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In recent years, model‐informed strategies such as the model integrated bioequivalence (MIBE) approach have gained significance due to their ability to enable decision making, streamline drug product development, and to waive bioequivalence studies, as applicable. In this work, we demonstrate the successful application of the MIBE approach that led to the waiver of a repeat fasting and fed bioequivalence studies for clopidogrel bisulfate 300 mg tablets. In the pivotal bioequivalence study, pharmacokinetic sampling in fasting and fed conditions was performed until 12 h, shorter than the recommended sampling up to at least three half‐lives of the drug. The mean half‐life of reference listed drug clopidogrel was 6 h. During dossier review, a query was received from the regulatory agency to assess the impact of early termination of the study on AUC 0–inf and bioequivalence assessment, although the pivotal study demonstrated average bioequivalence. To address this, a population pharmacokinetic model was developed under fasting and fed conditions based on the pilot study data that included data until 24 h. Further, the pivotal study pharmacokinetic parameters were predicted based on a model developed with pilot data and complete profiles until 10 half‐lives were simulated. The model‐derived parameters were utilized to assess preserving Type‐1 error rate at 5% and bioequivalence was simulated. The simulations demonstrated average bioequivalence under fasting and fed conditions, and the 90% confidence intervals within 80%–125%. Overall, the MIBE approach demonstrated that truncated sampling till 12 h did not compromise the interpretability of pivotal study, thereby alleviating the need for a repeat bioequivalence study.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ClopidogrelPlatelet Aggregation InhibitorsModels, BiologicalTherapeutic EquivalencyHumansFastingHalf-LifeMaleArea Under CurvePilot ProjectsAdultFemale

Stichwörter der Autor:innen

bioequivalencemodel integrated bioequivalencemodel integrated evidencepopulation pharmacokineticsregulatory

Substanzen

ClopidogrelPlatelet Aggregation Inhibitors

Autor:innen und Institutionen

  • Center for Translational Medicine, University of Maryland Baltimore, Baltimore, MD, USA.
  • Biopharmaceutics Group, Global Clinical Management, Dr. Reddy's Laboratories Ltd., Integrated Product Development Organization (IPDO), Hyderabad, Telangana, India.
  • Clinical Pharmacokinetics, Global Clinical Management, Dr. Reddy's Laboratories Ltd., Integrated Product Development Organization (IPDO), Hyderabad, Telangana, India.

ORCID-Profile: Mathangi Gopalakrishnan

Förderung

  • Dr. Reddy's Laboratories Ltd

Zitieren

APA

Gopalakrishnan, M., Bhattiprolu, A. K., Gobburu, J., Boddu, R., Kambam, V., Khan, S. M., Saini, A. K., & Kollipara, S. (2026). Leveraging Model Integrated Bioequivalence (MIBE) to Address Regulatory Concerns and Waive Repeat Bioequivalence Studies—A Case Study with Clopidogrel. The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.70142

Vancouver

Gopalakrishnan M, Bhattiprolu AK, Gobburu J, Boddu R, Kambam V, Khan SM, et al. Leveraging Model Integrated Bioequivalence (MIBE) to Address Regulatory Concerns and Waive Repeat Bioequivalence Studies—A Case Study with Clopidogrel. The Journal of Clinical Pharmacology. 2026. doi:10.1002/jcph.70142

BibTeX
@article{Gopalakrishnan2026,
  author = {Gopalakrishnan, Mathangi and Bhattiprolu, Adithya Karthik and Gobburu, Joga and Boddu, Rajkumar and Kambam, Veena and Khan, Sohel Mohammed and Saini, Anuj Kumar and Kollipara, Sivacharan},
  title = {Leveraging Model Integrated Bioequivalence (MIBE) to Address Regulatory Concerns and Waive Repeat Bioequivalence Studies—A Case Study with Clopidogrel},
  journal = {The Journal of Clinical Pharmacology},
  year = {2026},
  doi = {10.1002/jcph.70142}
}
Kostenlos starten →